VA Launched Psilocybin Clinical Trial for Veterans
The PIVOT study explores treatment-resistant depression using psychedelics, creating potential security clearance questions.
Updated on Sept. 22, 2026 in Military Jobs
Live Poll
Should participating in government-authorized clinical trials affect your security clearance eligibility?
In August 2026, the Department of Veterans Affairs initiated the PIVOT clinical trial to evaluate psilocybin as a therapy for treatment-resistant depression in veterans. The study is currently underway at five medical centers across the United States.
Why it matters
The research seeks to determine the safety and efficacy of psilocybin for veterans who have not responded to standard care, while highlighting the intersection of federal law and emerging medical treatments. Because psilocybin remains a Schedule I controlled substance, participation may raise compliance concerns regarding National Security Adjudicative Guidelines.
The PIVOT trial will enroll 240 veterans across 5 VA medical centers, representing a controlled effort to evaluate outcomes compared to standard, non-responsive treatment benchmarks.
The players
Department of Veterans Affairs
A federal cabinet-level agency responsible for managing the healthcare, benefits, and support services for veterans of the United States military.
The details
Under the PIVOT protocol, participants receive pharmaceutical-grade psilocybin within a clinical setting supported by professional therapeutic guidance. Researchers are monitoring changes in PTSD severity and depressive symptoms alongside patient-reported side effects. While the VA is also investigating MDMA-assisted therapy, it maintains a warning against the unauthorized use of psychedelics due to their federal status under Schedule I.
Timeline
The Department of Veterans Affairs announced the launch of the PIVOT trial in August 2026.
Market Landscape
This clinical trial operates against the backdrop of the National Security Adjudicative Guidelines, which govern how illegal drug use affects security clearance eligibility. The study marks a significant federal shift in investigating controlled substances, even as regulatory hurdles for cleared personnel remain.
Operators and hiring managers should monitor how government health initiatives regarding Schedule I substances influence future security clearance reviews. Professionals maintaining clearances should consult official guidance before participating in trials involving controlled substances.
The takeaway
The federal move toward psychedelic research signals a shift in treatment paradigms for treatment-resistant conditions. Organizations should review the National Security Adjudicative Guidelines to understand how federal medical participation intersects with employee clearance requirements.
Further reading
For broader context on federal employment requirements, explore Military Jobs.
Source note: This article includes information reported by ClearanceJobs.
Live Poll
Should participating in government-authorized clinical trials affect your security clearance eligibility?
